Erschienen in:
08.06.2019 | Guide Line
JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-5—diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)
verfasst von:
Ken Ohmachi
Erschienen in:
International Journal of Hematology
|
Ausgabe 2/2019
Einloggen, um Zugang zu erhalten
Excerpt
Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) as defined in the 2017 WHO classification [1] accounts for over 30% of all non-Hodgkin lymphomas (NHL) in Japan [2], making it the most prevalent form of NHL. DLBCL can occur as primary disease or through histologic transformation from other low-grade B-cell lymphoma, and is an inhomogeneous group of various entities. It can be classified into subtypes of germinal center B-cell lymphoma and active B-cell/non-germinal center B-cell lymphoma based on cell origin determined by immunohistochemical staining for markers such as CD10, BCL6, and IRF4/MUM1 [3]. However, treatment stratification by subtype is currently only performed in clinical trials. …